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An overactive Toll-like receptor (TLR) pathway is a hallmark of several autoimmune diseases and some 
types of B cell lymphomas. TLR signaling is a main mediator of inflammatory signals in B cells and causes 
NF-κB activation, which has numerous stimulatory effects, including promotion of B cell survival and pro-
liferation. A key factor in TLR signaling is the adaptor protein MyD88. Downstream of MyD88, the inter-
leukin-1 receptor–associated kinase 4 (IRAK4) links TLR signaling to the NF-κB pathway. Because of the 
overactive TLR signaling in several autoimmune diseases, and as some B cell lymphomas carry activating 
mutations in MyD88, there is strong interest in developing inhibitors of this pathway. MyD88 itself is not a 
promising target, because it is difficult to develop inhibitors for adaptor proteins. Fortunately, IRAK4 is 
essential for signaling through MyD88, and numerous examples of efficient kinase inhibitors exist. In this 
issue, Kelly et al. now succeed in identifying two novel and very promising IRAK4 inhibitors and present 
for the first time exciting preclinical studies with these molecules.
The two inhibitors, called ND-2158 and ND-2110, bind to the ATP pocket of IRAK4, thereby inhibiting its kinase activity. These 
two molecules have high affinities for IRAK4 and possess good pharmacological properties. Importantly, in a screen of 334 kinases, 
ND-2158 and ND-2110 proved to be highly specific for IRAK4. 
ND-2158 and ND-2110 were efficient in reducing disease sever-
ity in mouse models of pathological inflammatory responses. In 
studies with cell lines from diffuse large B cell lymphoma (DLBCL), 
specifically those lines of the activated B cell–like (ABC) subtype 
of DLBCL with a specific activating mutation in MyD88 (L265P), 
they showed inhibition of IRAK4 and NF-κB activity upon incu-
bation with these inhibitors. Xenograft studies with DLBCL cell 
lines revealed the in vivo efficiency of ND-2158 in reducing 
tumor growth. As it is likely that in a potential future clinical 
application IRAK4 inhibition alone may not be curative, the 
authors studied combined application of the IRAK4 inhibitors 
with inhibitors of other pathogenic factors in ABC DLBCL. For 
example, coapplication of ibrutinib, an inhibitor of B cell receptor 
signaling, which is chronically active in ABC DLBCL, had syn-
ergistic effects on tumor growth in mice.
The present study lays the ground for the development of 
clinical studies with the two IRAK4 inhibitors. It is impressive 
that this stage has already been reached, considering that 
MyD88 mutations were identified in ABC DLBCL only four 
years ago. As this type of DLBCL has the worst prognosis, and 
30% of ABC DLBCL carries the L265P mutation, this new 
treatment approach may be valuable for a substantial fraction 
of DLBCL patients. Furthermore, patients affected by several 
other types of B cell lymphomas carrying this mutation, or 
patients with autoimmune diseases might also benefit from 
treatment with these inhibitors. Considering the recent clinical 
success with ibrutinib in the treatment of ABC DLBCL, it is 
even more promising that combined treatment with ND-2158 
and ibrutinib shows synergistic therapeutic effects in these pre-
clinical studies. What remains currently puzzling is why two 
ABC DLBCL lines with MyD88 mutations other than L265P 
were not sensitive to the IRAK4 inhibitors. This warrants fur-
ther investigation.
Kelly, P.N., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/
jem.20151074
IRAK4 inhibition to shut down TLR signaling in 
autoimmunity and MyD88-dependent lymphomas
Insight from 
Ralf Küppers
The TLR pathway is overactivated in various types of inflammatory 
and autoimmune diseases by ligands binding to the TLR. In 30% of 
ABC DLBCL and in several other B cell lymphomas, MyD88, which links 
TLRs to the IRAK1 and IRAK4 kinases, is affected by activating L265P 
mutations. Activity of IRAKs leads to activation of the canonical NF-κB 
pathway. IRAK4 is essential for TLR signaling through MyD88. The 
newly developed IRAK4 inhibitors ND-2158 and ND-2110 abrogate 
signaling mediated by TLR receptors or mutated MyD88. In ABC DLBCL, 
NF-κB is also activated though chronic active B cell receptor signaling, 
which involves the Bruton’s tyrosine kinase (BTK). Inhibition of BTK by 
ibrutinib has shown clinical efficiency in first clinical studies. Notably, 
coapplication of ibrutininb and ND-2158 has synergistic toxic activity 
for ABC DLBCL cell lines in vitro and in a xenograft model. For the 
signaling pathways, not all components are shown.
Ralf Küppers, University of Duisburg-Essen, Essen: ralf.kueppers@uk-essen.de
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Tumor development involves a complex interplay between cancer cells and the surrounding 
microenvironment, including cancer-associated fibroblasts (CAFs). Whether such CAFs are 
tumor suppressive or tumor promoting remains a contentious issue, with obvious therapeutic 
implications regarding targeting of stromal cell populations in vivo.
In colorectal cancer, inflammation is strongly implicated in tumorigenesis. The NF-κB 
signaling pathway is of particular interest, as a key regulator of both inflammation and cancer. 
Previous studies from the group of Florian Greten and others have assessed the function of 
NF-κB signaling in intestinal epithelial cells at different stages during tumor growth. Two new 
studies, in this issue, have now investigated the stromal contribution of NF-κB signaling to 
colorectal tumorigenesis through deletion of the same gene in mesenchymal cells—with 
diametrically opposite results. Both groups took a broadly similar approach by deleting IKKβ 
(a mediator of NF-κB) in intestinal fibroblasts/CAFs, alongside chemical carcinogenesis (AOM/DSS). Using a ColVICre driver, 
Koliaraki et al. report that deletion of IKKβ in intestinal mesenchymal cells leads to decreased tumor incidence. Conversely, Pallangyo 
et al. report that deletion of IKKβ using a Col1a2Cre-ER driver stimulates intestinal epithelial cell proliferation and increased 
tumor size, suggesting an unexpected tumor-suppressive function for NF-κB signaling in CAFs. Interestingly, in the absence of 
inflammation, both models show no overt phenotype at homeostasis, suggesting that tissue damage is required.
This work can be put in the context of growing literature where the inhibition of stromal elements is hard to predict. 
For example, in pancreatic ductal adenocarcinoma (PDAC), activated stellate cells alter the tumor microenvironment, making the 
tumor refractory to drug treatment. It follows that depletion of the stroma should lead to therapeutic improvement. However, 
through targeted functional ablation of myofibroblasts, Raghu Kalluri and colleagues have revealed a tumor-suppressive role for 
the stroma in PDAC. In the mammary gland, Gustavo Leone’s group has shown that genetic inactivation of Pten in stromal fibro-
blasts accelerates the progression of mammary epithelial tumors. In the intestine, Tomi Mäkelä and colleagues have shown that 
LKB1 signaling in mesenchymal cells is required for suppression of gastrointestinal polyposis, whereas Gijs van den Brink’s group 
showed that Indian Hedgehog signaling from the stroma is required for adenoma formation. Therefore, a much more detailed 
study of the tumor-suppressive and tumor-promoting aspects of the tumor stroma is required, and this is likely to be tissue-tumor 
specific. Care should be taken in overinterpreting depletion studies, which may have dramatic effects on homeostasis.
Clearly work remains to reconcile these two new 
studies, specifically to determine if IKKβ is being 
deleted in distinct fibroblast populations through 
the use of different Cre drivers. Furthermore, it is pos-
sible that constitutive (ColVICre) versus inducible 
(Col1a2Cre-ER) deletion of IKKβ could have bio-
logical implications, particularly regarding genetic 
compensation mechanisms through development. 
Uniform analysis using the same conditionally inducible 
Cre driver, sampled at the same time point, will be 
essential here. Most importantly though, these results 
suggest there is heterogeneity in intestinal fibroblasts 
and that targeting pathways may have distinct outcomes 
in different fibroblast populations.
Together, these two studies offer very exciting 
new insights into NF-κB signaling in stromal fibro-
blasts in colitis-associated cancer and show that we 
are only just beginning to understand the complexity 
of the tumor microenvironment. Understanding the 
differences between these studies could offer profound 
new insights into fibroblast heterogeneity in the 
intestinal epithelium.
Koliaraki, V., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150542
Pallangyo, C.K., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150576
Genetic deletion of IKKβ in intestinal mesenchymal cells in the context of colitis-
associated tumorigenesis results in either a decrease (Koliaraki et al.) or an increase 
(Pallangyo et al.) in tumorigenesis, depending on the specific Cre recombinase used.
Robert P. Fordham and Owen J. Sansom, Cancer Research UK Beatson Institute: R.Fordham@beatson.gla.ac.uk and o.sansom@beatson.gla.ac.uk
Colon contradictions: NF-κB signaling in intestinal tumorigenesis
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A new study by Jörg Prinz’s group has identified a melanocyte-derived autoantigen that triggers T cell acti-
vation in psoriasis vulgaris. 
For two decades, psoriasis has been classified as a probable autoimmune disease based on a strong disease 
association with HLA-C*06:02, the ability of T cell–directed therapies to produce disease resolution, and the 
absence of a known infectious agent or exogenous antigen that triggers the disease. Only recently, there has 
been the suggestion that cathelicidin (LL37), a keratinocyte-derived antimicrobial peptide might serve as an 
autoantigen in psoriasis, but not all patients have T cell reactivity to this target. 
In this study, a second plausible antigen, ADAMTS-like protein 5 (ADAMTSL5) that is produced 
by melanocytes is identified as an activating antigen for IL-17–producing T cells that are restricted by 
HLA-C*06:02. The activation of 
IL-17–producing T cells is important, as increasing 
evidence places Th17 and Tc17 cells as the central 
pathogenic immune cells in psoriasis. Although 
T cells are found juxtaposed to melanocytes in 
psoriasis lesions, the type of response that is trig-
gered is not cytotoxic to melanocytes, and in fact, 
melanocytes are increased in psoriasis lesions, paral-
leling epidermal hyperplasia that is a key feature of 
this disease. 
From the standpoint of autoimmune responses 
that damage cells and tissues in many other organs, the 
response in psoriasis is distinctly different, as the im-
mune reaction triggers a wound-healing response 
pathway in the skin that can resolve with restoration 
of normal skin structure and function. In part, this 
may be related to the functions of Th17 and Tc17 
cells that, rather than serving as cytotoxic effectors, 
stimulate and amplify innate immune pathways in tar-
get cells. By targeting keratinocytes, IL-17 increases 
transcription of many antimicrobial proteins, including 
the autoantigen LL37, and induces the production of 
chemokines CXCL1, 2, 3, and 8, attracting neutro-
phils to the site of inflammation. Moreover, CXCL1 
may also amplify the autoimmune response because it 
was first identified as a melanocyte growth factor and 
might also drive melanocyte and ADAMTSL5 expan-
sion in psoriasis lesions.
This work has some other interesting pathogenic 
implications. First, the selective growth of melano-
cytes in skin epithelium may help to explain why pso-
riasis is largely a skin-restricted disease. Second, the 
absence of melanocytes from the interfollicular epi-
dermis in most nonhuman species may help to explain 
why a spontaneous psoriasis-like disease does not 
occur in lower species.
Arakawa, A., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/
jem.20151093
James G. Krueger, The Rockefeller University: kruegej@rockefeller.edu
An autoimmune “attack” on melanocytes tr iggers psor iasis  
and cellular hyperplasia
Insight from 
James Krueger
In psoriasis, CD8+ T cells recognize ADAMTSL5 as an autoantigen presented by 
melanocytes in HLA-C*06:02 molecules. ADAMTSL5 stimulation triggers the 
psoriasis signature cytokine, IL-17A.
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Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with AML deaths in 
the US reaching nearly 11,000 in 2014. Unfortunately, the clinical outcome of AML is poor, with the majority 
of patients experiencing relapse within three years. Frequent occurrence of comorbidities precludes treatment 
with a standard chemotherapy regimen, and the field continues to seek novel therapies that may target leu-
kemic stem cells (LSCs), felt to be the root cause of relapse and refractory disease. However, ideal targets for 
drug therapies remain elusive.
Hypoxia-inducible factor-1α (HIF-1α) is a subunit of a heterodimeric transcription factor containing a 
basic helix-loop-helix domain and represents the key transcriptional regulator of cellular and developmental 
response to low oxygen level (hypoxia). AML is initiated within the bone marrow (BM), likely under local 
hypoxic conditions. Recently, Dominique Bonnet and colleagues reported that shRNA-based down-regu-
lation of mediators of cellular responses to hypoxia, such as HIF-1α or HIF-2α, induces apoptosis and prevents leukemic en-
graftment upon transplantation into mice (the functional property that defines LSCs). This observation suggested that HIF-1α 
or HIF-2α is required for the maintenance of LSCs and may represent potential therapeutic targets for AML. In contrast, the 
group of Jörg Cammenga has recently shown that genetic deletion of Hif-1α has no effect on mouse AML maintenance, in-
troducing a contradiction in the role of HIFs in AML disease. A complete understanding of the role of HIFs in AML, however, 
is lacking and calls for sophisticated genetic approaches.
In this issue, Vukovic et al. develop a conditional genetic model to examine the impact of deletion of Hif-2α or both Hif-1α 
and Hif-2α at different stages of Meis1/Hoxa9- or MLL-AF9–driven leukemogenesis. The authors reveal that Hif-2α suppresses 
the development of LSCs but has no impact on AML propagation in a Meis1/Hoxa9-induced murine AML model. Hif-2α dele-
tion accelerates LSC development but does not affect LSC maintenance of Mll-AF9–driven AML. The lack of requirement for 
Hif-2α in AML propagation was surpris-
ing; thus, the Kranc group used the re-
cently available CRISPR-Cas9–mediated 
genome editing approach to determine 
the potential impact of HIF-2α ablation 
in human leukemic cells. HIF-2α abla-
tion had no effect on human AML lines, 
including on cell cycle regulation. In the 
context of therapeutic targeting, they 
used BAY 87–2243, a compound able to 
impair HIF-1α and HIF-2α protein ac-
cumulation under hypoxic conditions, 
to show that inhibition of the HIF path-
way has no effect on human AML cell 
survival or proliferation.
This study represents the first genetic 
evidence that Hif-2α may act as a tumor 
suppressor in AML development and/or 
initiation but is dispensable for LSC-based 
disease maintenance. Consistent with this 
idea, the authors show that Hif-1α and 
Hif-2α deletion promoted a gene expression signature that facilitated survival and proliferation of preleukemic cells and suggest 
that this is responsible for the selective effects of HIF pathway on leukemic initiation and not on AML established by LSC 
trasnplantation. Accordingly, this study questions the use of targeting HIFs in AML after critical events of leukemic initiation 
have occurred.
Before neglecting molecular or pharmacological targeting of HIF in AML, other caveats to these observations need to be explored. 
Like most drugs, the compound inhibitor used in this study, BAY 87–2243, has many modes of action, including the ability to affect 
mitochondrial functions. The importance of mitochondrial capacity and AML has been previously demonstrated by the Schimmer 
group, but it remains to be examined in a conditional deletion model similar to the one used by Vukovic et al. This may provide 
insights on the role of the HIF pathway and the metabolome of AML LSCs that have yet to be uncovered. Furthermore, as AML is a 
genetically heterogeneous cancer and is characterized by several molecular alterations, the current studies, like many recent reports for 
AML disease in vivo, are restricted to the Mll-AF9–Meis1/HoxA9–driven leukemia that represents only a fraction of human AMLs. 
Hypoxia factors suffocate leukemic stem cell initiation
Insight from 
Mick Bhatia
Under hypoxic conditions within the bone marrow, Hif-1α and Hif-2α act in a synergistic 
manner to suppress the establishment of LSCs from preleukemic cells, thus slowing down AML 
development. However, once LSCs are established, Hif-1α and Hif-2α are dispensable for LSC 
maintenance and leukemia propagation. Therefore, in this proposed model, Hif-1α and Hif-2α 
play different roles at distinct stages of AML leukemogenesis.
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Before any conclusions can be drawn, the role of HIFs and their pharmacological inhibition will need to be tested in other 
clinical models that capture the heterogeneity of patients and their response to chemotherapy. Mouse xenografts of human 
AML cells may serve as an experimental alternative to test the role of the HIF pathway in leukemia-initiating cells (LICs), using 
in vitro manipulation of the pathway to quantitatively determine the effects on frequency of transplanted human LICs from a 
diverse set of AML patients. Because HIFs are known to regulate SDF-1 in the BM niche, it would also be interesting to target 
this pathway in mice with established human AML and investigate the effect of the tumor microenvironment on LSC function 
in vivo.
Until then, distinguishing the effects on leukemia initiation versus maintenance by targeting the HIF pathway and demon-
strating the selectivity for “preleukemic cells,” as opposed to normal HSCs, is where the low-hanging oxygen may lie in the 
treatment or prevention of AML.
Vukovic, M., et al. 2015. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150452
Mick Bhatia, McMaster Stem Cell and Cancer Research Institute: mbhatia@mcmaster.ca
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